Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMFQEA6)

Drug Name
Pembrolizumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [2]
Breast cancer 2C60-2C65 Phase 3 [3]
Colorectal cancer 2B91.Z Phase 3 [3]
Esophageal cancer 2B70 Phase 3 [3]
Hepatocellular carcinoma 2C12.02 Phase 3 [3]
Renal cell carcinoma 2C90 Phase 3 [3]
Small-cell lung cancer 2C25.Y Phase 3 [3]
Cutaneous squamous cell carcinoma 2C30 Phase 2 [4]
Ovarian cancer 2C73 Phase 2 [3]
Prostate cancer 2C82.0 Phase 2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
Primary mediastinal B-cell lymphoma 2A81 Application submitted [3]
Cross-matching ID
TTD Drug ID
DMFQEA6

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Not Available [5]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Programmed cell death protein 1 (PD-1) DTT PDCD1 5.635 4.661 4.706 5.15
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Skin
The Studied Disease Melanoma [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death protein 1 (PD-1) DTT PDCD1 7.26E-01 -0.01 -0.03
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
2 Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023 Apr 10;41(11):1992-1998.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.